Details of the presentation are as follows:
- KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation (Poster # 2036) by
Sujatha Muralidharan1, Brendan J. Classon1, Karalyne Crowder2, Andrea S.L. Wong2, Yoshinobu Yokota2, Florence Burleson3, Tracy Garron1, Moses Njenga1, John F. Paolini1 will be presented during Poster Session 2 on Tuesday, April 9th, 2019 at 7:30 p.m. Mountain Timein the Breckenridge Ballroomat the Beaver Run Resort. Kiniksa intends to make the materials available through the Investors and Media section of its website (www.kiniksa.com).
KPL-404 is an investigational humanized monoclonal antibody that is designed to inhibit the CD40-CD40-ligand interaction, a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching. Dysregulation of the CD40-CD40L pathway has been implicated in multiple autoimmune disease pathologies such as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren’s Syndrome and Grave’s Disease.
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.
Every Second Counts!™
Kiniksa Investor and Media Contact
Source: Kiniksa Pharmaceuticals, Ltd.